X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (235) 235
female (152) 152
male (139) 139
middle aged (123) 123
pulmonary embolism (102) 102
hematology (98) 98
aged (97) 97
diagnosis (92) 92
adult (77) 77
peripheral vascular disease (71) 71
risk factors (71) 71
venous thromboembolism (64) 64
pulmonary embolism - diagnosis (60) 60
management (59) 59
anticoagulants (57) 57
prospective studies (57) 57
abridged index medicus (56) 56
thromboembolism (53) 53
thrombosis (51) 51
d-dimer (50) 50
anticoagulants - therapeutic use (49) 49
medicine, general & internal (49) 49
risk (47) 47
warfarin (43) 43
deep-vein thrombosis (41) 41
treatment outcome (41) 41
recurrence (39) 39
venous thrombosis (38) 38
aged, 80 and over (37) 37
acute disease (36) 36
respiratory system (36) 36
algorithms (35) 35
cardiac & cardiovascular systems (35) 35
mortality (34) 34
patients (34) 34
care and treatment (33) 33
time factors (33) 33
angiography (32) 32
atrial fibrillation (32) 32
hemorrhage - chemically induced (32) 32
stroke (32) 32
prevention (30) 30
prognosis (30) 30
pulmonary embolism - diagnostic imaging (30) 30
safety (30) 30
therapy (30) 30
anticoagulants - adverse effects (28) 28
follow-up studies (28) 28
computed-tomography (27) 27
fibrin fibrinogen degradation products - analysis (26) 26
incidence (26) 26
anticoagulants - administration & dosage (25) 25
cardiac arrhythmia (25) 25
dabigatran (25) 25
probability (25) 25
cohort studies (24) 24
pulmonary embolism - blood (24) 24
analysis (23) 23
research (23) 23
predictive value of tests (22) 22
sensitivity and specificity (22) 22
health aspects (21) 21
retrospective studies (21) 21
drug therapy (20) 20
risk assessment (20) 20
internal medicine (19) 19
pregnancy (19) 19
prevalence (19) 19
pulmonary embolism - drug therapy (19) 19
rivaroxaban (19) 19
clinical trials (18) 18
critical care medicine (18) 18
embolisms (18) 18
guidelines (18) 18
oral anticoagulants (18) 18
pulmonary embolism - mortality (18) 18
risk-factors (18) 18
ultrasonography (18) 18
administration, oral (17) 17
atrial fibrillation - drug therapy (17) 17
bleeding (17) 17
cancer (17) 17
computed tomography (17) 17
hematology, oncology and palliative medicine (17) 17
molecular-weight heparin (17) 17
neoplasms - complications (17) 17
pulmonary embolism - complications (17) 17
pulmonary-embolism (17) 17
usage (17) 17
adolescent (16) 16
anticoagulation (16) 16
decision support techniques (16) 16
hypertension (16) 16
medicine (16) 16
netherlands (16) 16
surgery (16) 16
tomography, x-ray computed (16) 16
venous thrombosis - diagnosis (16) 16
aspirin (15) 15
atrial-fibrillation (15) 15
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 6, pp. 511 - 520
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 5, pp. 431 - 441
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2011, Volume 29, Issue 17, pp. 2405 - 2409
Purpose The routine use of modern computed tomography scanners has led to an increased detection of incidental pulmonary embolism (PE), in particular in... 
ONCOLOGY | ONCOLOGY PATIENTS | PREVALENCE | Recurrence | Hemorrhage - epidemiology | Humans | Middle Aged | Anticoagulants - therapeutic use | Male | Incidence | Venous Thromboembolism - etiology | Pulmonary Embolism - mortality | Neoplasms - complications | Adult | Female | Aged | Retrospective Studies | Venous Thromboembolism - epidemiology | Cohort Studies
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 380, Issue 12, pp. 1139 - 1149
CT pulmonary angiography is a standard diagnostic method for pulmonary embolism, but in pregnant women, this imaging test could expose mother and child to... 
Acute Disease | Prospective Studies | Humans | yes | Venous Thrombosis/diagnosis | Venous Thromboembolism/diagnosis | Computed Tomography Angiography | Pregnancy | Hemoptysis | Algorithms | Pulmonary Embolism/diagnosis | Adult | Female | Fibrin Fibrinogen Degradation Products/analysis | Pregnancy Complications, Cardiovascular/diagnosis | DECISION RULE | WELLS RULE | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | VENOUS THROMBOEMBOLISM | POSTPARTUM | GUIDELINES | CLINICAL PROBABILITY | D-DIMER | Venous Thrombosis - diagnosis | Pregnancy Complications, Cardiovascular - diagnostic imaging | Fibrin Fibrinogen Degradation Products - analysis | Pulmonary Embolism - diagnosis | Pregnancy Complications, Cardiovascular - diagnosis | Pulmonary Embolism - diagnostic imaging | Venous Thromboembolism - diagnosis | Pulmonary embolism | CT imaging | Symptomatology | Usage | Pregnant women | Diagnosis | Research | Health aspects | Cardiac arrhythmia | Compression | Medical imaging | Angiography | Embolisms | Fetuses | Medical diagnosis | Thrombosis | Patients | Evidence-based medicine | Embolism | Dyspnea | Computed tomography | Perfusion | Violations | Womens health | Ventilation | Thromboembolism | Health risk assessment | Ultrasound | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
PloS one, ISSN 1932-6203, 04/2015, Volume 10, Issue 4, p. e0122520
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2008, Volume 358, Issue 26, pp. 2765 - 2775
... Enoxaparin for Thromboprophylaxis after Hip Arthroplasty Bengt I. Eriksson, M.D., Ph.D., Lars C. Borris, M.D., Richard J. Friedman, M.D., Sylvia Haas, M.D., Menno V... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
American Journal of Emergency Medicine, ISSN 0735-6757, 2016, Volume 34, Issue 11, pp. 46 - 51
Abstract As expected with all antithrombotic agents, there is a risk of bleeding complications in patients receiving direct oral anticoagulants (DOACs) because... 
Emergency | ANTIDOTE | ANDEXANET ALPHA | DABIGATRAN | MANAGEMENT | EFFICACY | PHARMACOKINETICS | EMERGENCY MEDICINE | WARFARIN | SAFETY | ORAL ANTICOAGULANTS | TOLERABILITY | Piperazines - administration & dosage | Recombinant Proteins - therapeutic use | Factor Xa - administration & dosage | Dabigatran - adverse effects | Humans | Clinical Protocols | Hemorrhage - prevention & control | Thiazoles - antagonists & inhibitors | Recombinant Proteins - adverse effects | Arginine - analogs & derivatives | Thiazoles - adverse effects | Arginine - administration & dosage | Patient Selection | Pyridines - antagonists & inhibitors | Pyridines - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Rivaroxaban - adverse effects | Emergency Treatment | Factor Xa - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Surgical Procedures, Operative | Piperazines - therapeutic use | Pyridones - antagonists & inhibitors | Dabigatran - antagonists & inhibitors | Anticoagulants - adverse effects | Piperazines - adverse effects | Recombinant Proteins - administration & dosage | Hospitals | Factor Xa Inhibitors - adverse effects | Arginine - adverse effects | Rivaroxaban - antagonists & inhibitors | Hemorrhage - chemically induced | Arginine - therapeutic use | Pyrazoles - antagonists & inhibitors | Pyridones - adverse effects | Practice Guidelines as Topic | Periodical publishing | Anticoagulants (Medicine) | Prothrombin | Thrombin | Comorbidity | Anticoagulants | FDA approval | Laboratories | Hemorrhage
Journal Article